GlassScriptPhysician profile
Abbey Lynn Cocuzza
NPI 1316611254
$3,659.22
in general payments reported to CMS, 2019-2025
32 companies · $600 in 2025
The $600 reported for 2025 was more than what 77% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
See the full distribution for Gerontology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $38.95 · 2023: $1,116 · 2024: $1,904 · 2025: $600.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,620.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,620.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $615.40 | 2022-2025 | Repatha, Repatha |
| Novo Nordisk INC | $310.75 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $221.43 | 2023-2024 | |
| Boston Scientific Corporation | $219.22 | 2024-2025 | Watchman Flx, Spaceoar System |
| Janssen Pharmaceuticals, INC | $212.58 | 2023-2024 | Xarelto |
| Cvrx, INC. | $178.85 | 2024-2025 | Barostim Neo System |
| Esperion Therapeutics, INC. | $172.37 | 2023-2024 | Nexletol |
| Merck Sharp & Dohme LLC | $170.47 | 2023-2025 | Verquvo, Capvaxive |
| Scpharmaceuticals INC. | $166.56 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $144.01 | 2023-2025 | Farxiga |
| Alnylam Pharmaceuticals INC. | $139.40 | 2023-2025 | Onpattro, Amvuttra |
| E.R. Squibb & Sons, L.L.C. | $136.38 | 2023 | Eliquis |
| Irhythm Technologies, INC. | $127.03 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $109.45 | 2024-2025 | Lifevest |
| Kiniksa Pharmaceuticals International, Plc | $82.23 | 2024 | Arcalyst |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $75.11 | 2024 | |
| Pfizer INC. | $68.49 | 2023-2024 | |
| Lexicon Pharmaceuticals, INC. | $67.92 | 2023-2024 | Inpefa |
| Lilly USA, LLC | $61.78 | 2024-2025 | Zepbound, Jardiance |
| Kiniksa Pharmaceuticals, LTD. | $58.27 | 2023 | Arcalyst |
| Kowa Pharmaceuticals America, INC. | $50.11 | 2023 | Livalo |
| Philips North America LLC | $45.56 | 2024 | (5044) Mcot |
| Amarin Pharma, INC. | $40.89 | 2022-2023 | |
| Impulse Dynamics (USA) INC. | $31.75 | 2024 | Optimizer |
| Kestra Medical Technology Services, INC. | $27.82 | 2025 | Assure Wcd |
| Bayer Healthcare Pharmaceuticals INC. | $22.65 | 2025 | |
| Genzyme Corporation | $21.97 | 2024 | |
| Watermark Medical, INC. | $18.92 | 2024 | |
| Bridgebio Pharma, INC. | $18.47 | 2025 | Attruby |
| Azurity Pharmaceuticals, INC. | $15.14 | 2025 | Edarbyclor |
| Regeneron Healthcare Solutions, INC. | $14.32 | 2023 | Evkeeza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.92 | 2023 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abbey Cocuzza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.